Galderma’s Nemluvio shows sustained improvements in moderate-to-severe atopic dermatitis
Up to 91% of patients achieved at least 75% improvement in eczema severity and up to 67% achieved near-complete skin clearance
Read More
Oct 2, 2026 | News
Up to 91% of patients achieved at least 75% improvement in eczema severity and up to 67% achieved near-complete skin clearance
Read MoreOct 2, 2026 | News
Patchefsky most recently served as Global Client Director at Havas Health & You
Read MoreOct 1, 2026 | News
Tulisokibart was designed to help address immuno-fibrosis, a key driver of disease progression in HS
Read MoreSep 30, 2026 | News, Regulatory
If approved, this treatment would offer a new option for the nearly one million Americans living with MS
Read MoreSep 29, 2026 | News, Regulatory
Desmoid tumours are rare soft tissue tumours that can grow aggressively into nearby tissues
Read MoreSep 28, 2026 | News, Regulatory
Treatment with Olumiant resulted in substantial scalp hair regrowth, as well as improvements in eyebrows and eyelashes
Read MoreSep 25, 2026 | News, Regulatory
The treatment is for adults in combination with atezolizumab
Read MoreThe deal focuses on addressing critical unmet medical needs
Read MoreSep 23, 2026 | News, Regulatory
Trixeo is the first and only triple-combination therapy approved in the EU for patients 12 years and older, independent of exacerbation history
Read MoreSep 22, 2026 | News, Healthcare
The partnership introduces a world-first flu vaccine and extends the health security pandemic agreement
Read MoreThe Board will advise Galimedix on scientific and clinical strategy
Read MoreSep 21, 2026 | News, Regulatory
If approved, this would be the first IL-17A inhibitor licensed in Europe for adults with polymyalgia rheumatica
Read More
